August 2016- Volume 12, Issue 8

August 2016

In this Issue

Diagnostics

New information about kataegis offers hope

New information about kataegis offers hope

Genetic phenomenon proves to be a positive marker in breast cancer

Mammary marker

Mammary marker

IVD test aids in breast cancer subtyping

Owlstone Medical closes $7M investment to commercialize disease breathalyzer

Owlstone Medical closes $7M investment to commercialize disease breathalyzer

Owlstone Medical Ltd. was recently spun out of parent company Owlstone Inc. to develop and commercialize a breathalyzer for use in clinical diagnostics and precision medicine

Bio-Techne acquires Advanced Cell Diagnostics

Bio-Techne acquires Advanced Cell Diagnostics

$250-million-plus deal marks Bio-Techne’s entry into the realm of genomics

Contract Services

WuXi AppTec expands reach with Reaxys license

WuXi AppTec expands reach with Reaxys license

Company plans to leverage database for synthetic, medicinal chemistry research

Cloud collaboration yields fruit

Cloud collaboration yields fruit

A multi-institution team devises new prodrug, points to PLA2 as an IBD target

Crown Bioscience strengthens immuno-oncology platform

Crown Bioscience strengthens immuno-oncology platform

Company announces the launch of the OmniScreen cell panel screening platform

Clinical Trials

A new RESORCE for cancer patients?

A new RESORCE for cancer patients?

RESORCE study finds Stivarga could improve overall survival in liver cancer

Novartis makes progress with SM

Novartis makes progress with SM

Study shows promise for patients with systemic mastocytosis

Culture of clinical trial management

Culture of clinical trial management

SCORR report explains challenges and expectations of project management

A new tactic for treating T1D

A new tactic for treating T1D

Sernova receives funding from JDRF to advance its diabetes cell therapy to a clinical trial

In with ZGN-1061, out with beloranib

In with ZGN-1061, out with beloranib

Zafgen shifts focus to second-gen MetAP2 inhibitor in wake of troubles around PWS candidate

Esperion provides update for bempedoic acid

Esperion provides update for bempedoic acid

Esperion Therapeutics Inc. recently provided updates on the bempedoic acid (ETC-1002) clinical development program and regulatory plans

Discovery

Investigating the disease connection

Investigating the disease connection

NIH research into Gaucher disease uncovers a molecule that could also treat Parkinson’s

A fresh look at polycystic kidney disease

A fresh look at polycystic kidney disease

Virtual tissue technology helps Indiana University researchers find new drug target

Progress with proteins

Progress with proteins

TSRI teams report on work that could boost anticancer efforts and drug development

Five Prime collaborates with University of Minnesota

Five Prime collaborates with University of Minnesota

The organizations are partnering to expand hematopoietic stem cell options

Research & Development

Two for biopharmaceutical characterization

Two for biopharmaceutical characterization

Thermo Fisher and NIBRT pursue analytical solutions designed to streamline workflows, quickly generate data

Possible explanation for lithium efficacy

Possible explanation for lithium efficacy

Pharmacological success as a mood stabilizer poorly understood

Novel data confirm optimal drug-like properties of BiXAb antibodies

Novel data confirm optimal drug-like properties of BiXAb antibodies

BiXAb ‘plug-and-play’ bispecific antibodies reportedly demonstrated excellent in-vitro properties and in-vivo activity

Reliable and robust

Reliable and robust

Probiodrug and Crossbeta create strategic partnership for Alzheimer’s disease biomarkers

Building a better way of cancer modeling

Building a better way of cancer modeling

International collaboration plans to create new cancer cell culture models to accelerate research

Preclinical

Lupus drug moves forward

Lupus drug moves forward

Dalazatide found to suppress cytokines associated with lupus nephritis in children and teens

Getting ahead with GWAS

Getting ahead with GWAS

Research team uses new genomic testing technique to link mouse genes with behavioral traits

Silenc(ing) disease-driving genes is golden

Silenc(ing) disease-driving genes is golden

Dicerna unveils new preclinical data for GalXC delivery of RNAi-based therapy in fight vs. chronic liver disease

Managing mast cells with masitinib

Managing mast cells with masitinib

AB Science tyrosine kinase inhibitor shows potential in mediating ALS progression

Business & Government Policy

A busy June for Teva

A busy June for Teva

Pharma giant inks several agreements divesting assets in preparation for closing Allergan generics deal

Aligning drugs and diagnostics

Aligning drugs and diagnostics

FDA releases draft guidance to outline principles of codeveloping therapeutics and companion diagnostics

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

BioTek Instruments embarks on major site expansion

BioTek Instruments embarks on major site expansion

July sees start of $4-million facility expansion to meet company’s growing manufacturing and design needs

Samsung Bioepis a step closer to marketing Humira biosimilar in Europe

Samsung Bioepis a step closer to marketing Humira biosimilar in Europe

Marketing Authorization Application for SB5 adalimumab biosimilar candidate accepted for review by the EMA

Special Reports

Q&A

Q&A: A conversation on Coversin

Q&A: A conversation on Coversin

Gur Roshwalb expands on the complement system and its treatment candidate for rare diseases triggered by complement dysregulation

Editor's Focus

Life sciences and pharma in ‘black and white’

Life sciences and pharma in ‘black and white’

True representation of the population in clinical trials is something we aren't yet achieving, but we need to get closer to that goal even if we never do truly reach it

Commentary

Moonshot for pediatric pharmacology

Moonshot for pediatric pharmacology

Children tend to get left out in the cold when it comes to clinical research, but they are an important population that deserves better consideration when it comes to developing therapeutics

Market insight: The changing biopharma risk equation

Market insight: The changing biopharma risk equation

MilliporeSigma in June announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022